Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data

• Váldodahkkit: Frank van den Ouweland (Dahkki), Nicola Charpentier (Dahkki), Özlem Türeci (Dahkki), Ruben Rizzi (Dahkki), Federico J. Mensa (Dahkki), Claudia Lindemann (Dahkki), Shanti Pather (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

ABSTRACTThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to urgent actions by innovators, vaccine developers, regulators, and other stakeholders to ensure public access to protective vaccines while maintaining regulatory agency standards. Although development t...